AustralieFrV1, PubMed, Checkpoint, bibRecord, 001D50

Global strategies are required to cure and eliminate HBV infection.

Identifieur interne : 001D50 ( PubMed/Checkpoint ); précédent : 001D49; suivant : 001D51

Global strategies are required to cure and eliminate HBV infection.

Auteurs : Peter Revill [Australie] ; Barbara Testoni [France] ; Stephen Locarnini [Australie] ; Fabien Zoulim [France]

Source :

Nature reviews. Gastroenterology & hepatology [ 1759-5053 ] ; 2016.

RBID : pubmed:26907881

Descripteurs français

KwdFr :
- Antiviraux (usage thérapeutique), Coopération internationale, Découverte de médicament (organisation et administration), Découverte de médicament (économie), Essais cliniques comme sujet (économie), Humains, Hépatite B chronique (), Hépatite B chronique (immunologie), Hépatite B chronique (traitement médicamenteux), Hépatite B chronique (virologie), Politique de santé, Promotion de la santé (organisation et administration), Promotion de la santé (économie), Santé mondiale, Soutien financier à la recherche comme sujet.
MESH :
- immunologie : Hépatite B chronique.
- organisation et administration : Découverte de médicament, Promotion de la santé.
- traitement médicamenteux : Hépatite B chronique.
- usage thérapeutique : Antiviraux.
- virologie : Hépatite B chronique.
- économie : Découverte de médicament, Essais cliniques comme sujet, Promotion de la santé.
- Coopération internationale, Humains, Hépatite B chronique, Politique de santé, Santé mondiale, Soutien financier à la recherche comme sujet.

English descriptors

KwdEn :
- Antiviral Agents (therapeutic use), Clinical Trials as Topic (economics), Drug Discovery (economics), Drug Discovery (organization & administration), Global Health, Health Policy, Health Promotion (economics), Health Promotion (organization & administration), Hepatitis B, Chronic (drug therapy), Hepatitis B, Chronic (immunology), Hepatitis B, Chronic (prevention & control), Hepatitis B, Chronic (virology), Humans, International Cooperation, Research Support as Topic.
MESH :
- chemical , therapeutic use : Antiviral Agents.
- drug therapy : Hepatitis B, Chronic.
- economics : Clinical Trials as Topic, Drug Discovery, Health Promotion.
- immunology : Hepatitis B, Chronic.
- organization & administration : Drug Discovery, Health Promotion.
- prevention & control : Hepatitis B, Chronic.
- virology : Hepatitis B, Chronic.
- Global Health, Health Policy, Humans, International Cooperation, Research Support as Topic.

Abstract

Chronic HBV infection results in >1 million deaths per year from cirrhosis and liver cancer. No known cure for chronic HBV exists, due in part to the continued presence of transcriptionally active DNA in the nucleus that is not directly targeted by current antiviral therapies. A coordinated approach is urgently needed to advance an HBV cure worldwide, such as those established in the HIV field. We propose the establishment of an International Coalition to Eliminate Hepatitis B Virus (ICE-HBV) to facilitate the formation of international working groups on HBV virology, immunology, innovative tools and clinical trials: to promote awareness and education as well as to drive changes in government policy and ensure funds are channelled to HBV cure research and drug development. With the ICE-HBV in place, it should be possible to enable a HBV cure within the next decade.

DOI: 10.1038/nrgastro.2016.7
PubMed: 26907881

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 002057
to stream PubMed, to step Curation: 002032

Links to Exploration step

pubmed:26907881

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Global strategies are required to cure and eliminate HBV infection.</title>
<author><name sortKey="Revill, Peter" sort="Revill, Peter" uniqKey="Revill P" first="Peter" last="Revill">Peter Revill</name>
<affiliation wicri:level="1"><nlm:affiliation>Victorian Infectious Disease Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Victoria, 3010 Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Victorian Infectious Disease Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Victoria</wicri:regionArea>
<wicri:noRegion>Victoria</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Testoni, Barbara" sort="Testoni, Barbara" uniqKey="Testoni B" first="Barbara" last="Testoni">Barbara Testoni</name>
<affiliation wicri:level="1"><nlm:affiliation>Cancer Research Center of Lyon, INSERM U1052 and CNRS 5286, Lyon University, and Hospices Civils de Lyon, 151 Cours Albert Thomas, 69003 Lyon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Cancer Research Center of Lyon, INSERM U1052 and CNRS 5286, Lyon University, and Hospices Civils de Lyon, 151 Cours Albert Thomas, 69003 Lyon</wicri:regionArea>
<wicri:noRegion>69003 Lyon</wicri:noRegion>
<placeName><settlement type="city">Lyon</settlement>
<region type="region" nuts="2">Auvergne-Rhône-Alpes</region>
<region type="old region" nuts="2">Rhône-Alpes</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Locarnini, Stephen" sort="Locarnini, Stephen" uniqKey="Locarnini S" first="Stephen" last="Locarnini">Stephen Locarnini</name>
<affiliation wicri:level="1"><nlm:affiliation>Victorian Infectious Disease Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Victoria, 3010 Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Victorian Infectious Disease Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Victoria</wicri:regionArea>
<wicri:noRegion>Victoria</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zoulim, Fabien" sort="Zoulim, Fabien" uniqKey="Zoulim F" first="Fabien" last="Zoulim">Fabien Zoulim</name>
<affiliation wicri:level="1"><nlm:affiliation>Cancer Research Center of Lyon, INSERM U1052 and CNRS 5286, Lyon University, and Hospices Civils de Lyon, 151 Cours Albert Thomas, 69003 Lyon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Cancer Research Center of Lyon, INSERM U1052 and CNRS 5286, Lyon University, and Hospices Civils de Lyon, 151 Cours Albert Thomas, 69003 Lyon</wicri:regionArea>
<wicri:noRegion>69003 Lyon</wicri:noRegion>
<placeName><settlement type="city">Lyon</settlement>
<region type="region" nuts="2">Auvergne-Rhône-Alpes</region>
<region type="old region" nuts="2">Rhône-Alpes</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:26907881</idno>
<idno type="pmid">26907881</idno>
<idno type="doi">10.1038/nrgastro.2016.7</idno>
<idno type="wicri:Area/PubMed/Corpus">002057</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002057</idno>
<idno type="wicri:Area/PubMed/Curation">002032</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002032</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002032</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002032</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Global strategies are required to cure and eliminate HBV infection.</title>
<author><name sortKey="Revill, Peter" sort="Revill, Peter" uniqKey="Revill P" first="Peter" last="Revill">Peter Revill</name>
<affiliation wicri:level="1"><nlm:affiliation>Victorian Infectious Disease Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Victoria, 3010 Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Victorian Infectious Disease Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Victoria</wicri:regionArea>
<wicri:noRegion>Victoria</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Testoni, Barbara" sort="Testoni, Barbara" uniqKey="Testoni B" first="Barbara" last="Testoni">Barbara Testoni</name>
<affiliation wicri:level="1"><nlm:affiliation>Cancer Research Center of Lyon, INSERM U1052 and CNRS 5286, Lyon University, and Hospices Civils de Lyon, 151 Cours Albert Thomas, 69003 Lyon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Cancer Research Center of Lyon, INSERM U1052 and CNRS 5286, Lyon University, and Hospices Civils de Lyon, 151 Cours Albert Thomas, 69003 Lyon</wicri:regionArea>
<wicri:noRegion>69003 Lyon</wicri:noRegion>
<placeName><settlement type="city">Lyon</settlement>
<region type="region" nuts="2">Auvergne-Rhône-Alpes</region>
<region type="old region" nuts="2">Rhône-Alpes</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Locarnini, Stephen" sort="Locarnini, Stephen" uniqKey="Locarnini S" first="Stephen" last="Locarnini">Stephen Locarnini</name>
<affiliation wicri:level="1"><nlm:affiliation>Victorian Infectious Disease Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Victoria, 3010 Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Victorian Infectious Disease Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Victoria</wicri:regionArea>
<wicri:noRegion>Victoria</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zoulim, Fabien" sort="Zoulim, Fabien" uniqKey="Zoulim F" first="Fabien" last="Zoulim">Fabien Zoulim</name>
<affiliation wicri:level="1"><nlm:affiliation>Cancer Research Center of Lyon, INSERM U1052 and CNRS 5286, Lyon University, and Hospices Civils de Lyon, 151 Cours Albert Thomas, 69003 Lyon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Cancer Research Center of Lyon, INSERM U1052 and CNRS 5286, Lyon University, and Hospices Civils de Lyon, 151 Cours Albert Thomas, 69003 Lyon</wicri:regionArea>
<wicri:noRegion>69003 Lyon</wicri:noRegion>
<placeName><settlement type="city">Lyon</settlement>
<region type="region" nuts="2">Auvergne-Rhône-Alpes</region>
<region type="old region" nuts="2">Rhône-Alpes</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Nature reviews. Gastroenterology & hepatology</title>
<idno type="eISSN">1759-5053</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (therapeutic use)</term>
<term>Clinical Trials as Topic (economics)</term>
<term>Drug Discovery (economics)</term>
<term>Drug Discovery (organization & administration)</term>
<term>Global Health</term>
<term>Health Policy</term>
<term>Health Promotion (economics)</term>
<term>Health Promotion (organization & administration)</term>
<term>Hepatitis B, Chronic (drug therapy)</term>
<term>Hepatitis B, Chronic (immunology)</term>
<term>Hepatitis B, Chronic (prevention & control)</term>
<term>Hepatitis B, Chronic (virology)</term>
<term>Humans</term>
<term>International Cooperation</term>
<term>Research Support as Topic</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (usage thérapeutique)</term>
<term>Coopération internationale</term>
<term>Découverte de médicament (organisation et administration)</term>
<term>Découverte de médicament (économie)</term>
<term>Essais cliniques comme sujet (économie)</term>
<term>Humains</term>
<term>Hépatite B chronique ()</term>
<term>Hépatite B chronique (immunologie)</term>
<term>Hépatite B chronique (traitement médicamenteux)</term>
<term>Hépatite B chronique (virologie)</term>
<term>Politique de santé</term>
<term>Promotion de la santé (organisation et administration)</term>
<term>Promotion de la santé (économie)</term>
<term>Santé mondiale</term>
<term>Soutien financier à la recherche comme sujet</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hepatitis B, Chronic</term>
</keywords>
<keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Clinical Trials as Topic</term>
<term>Drug Discovery</term>
<term>Health Promotion</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Hépatite B chronique</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Hepatitis B, Chronic</term>
</keywords>
<keywords scheme="MESH" qualifier="organisation et administration" xml:lang="fr"><term>Découverte de médicament</term>
<term>Promotion de la santé</term>
</keywords>
<keywords scheme="MESH" qualifier="organization & administration" xml:lang="en"><term>Drug Discovery</term>
<term>Health Promotion</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Hepatitis B, Chronic</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Hépatite B chronique</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Hépatite B chronique</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Hepatitis B, Chronic</term>
</keywords>
<keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Découverte de médicament</term>
<term>Essais cliniques comme sujet</term>
<term>Promotion de la santé</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Global Health</term>
<term>Health Policy</term>
<term>Humans</term>
<term>International Cooperation</term>
<term>Research Support as Topic</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Coopération internationale</term>
<term>Humains</term>
<term>Hépatite B chronique</term>
<term>Politique de santé</term>
<term>Santé mondiale</term>
<term>Soutien financier à la recherche comme sujet</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Chronic HBV infection results in >1 million deaths per year from cirrhosis and liver cancer. No known cure for chronic HBV exists, due in part to the continued presence of transcriptionally active DNA in the nucleus that is not directly targeted by current antiviral therapies. A coordinated approach is urgently needed to advance an HBV cure worldwide, such as those established in the HIV field. We propose the establishment of an International Coalition to Eliminate Hepatitis B Virus (ICE-HBV) to facilitate the formation of international working groups on HBV virology, immunology, innovative tools and clinical trials: to promote awareness and education as well as to drive changes in government policy and ensure funds are channelled to HBV cure research and drug development. With the ICE-HBV in place, it should be possible to enable a HBV cure within the next decade.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26907881</PMID>
<DateCreated><Year>2016</Year>
<Month>03</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted><Year>2016</Year>
<Month>08</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>03</Month>
<Day>27</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1759-5053</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>13</Volume>
<Issue>4</Issue>
<PubDate><Year>2016</Year>
<Month>04</Month>
</PubDate>
</JournalIssue>
<Title>Nature reviews. Gastroenterology & hepatology</Title>
<ISOAbbreviation>Nat Rev Gastroenterol Hepatol</ISOAbbreviation>
</Journal>
<ArticleTitle>Global strategies are required to cure and eliminate HBV infection.</ArticleTitle>
<Pagination><MedlinePgn>239-48</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/nrgastro.2016.7</ELocationID>
<Abstract><AbstractText>Chronic HBV infection results in >1 million deaths per year from cirrhosis and liver cancer. No known cure for chronic HBV exists, due in part to the continued presence of transcriptionally active DNA in the nucleus that is not directly targeted by current antiviral therapies. A coordinated approach is urgently needed to advance an HBV cure worldwide, such as those established in the HIV field. We propose the establishment of an International Coalition to Eliminate Hepatitis B Virus (ICE-HBV) to facilitate the formation of international working groups on HBV virology, immunology, innovative tools and clinical trials: to promote awareness and education as well as to drive changes in government policy and ensure funds are channelled to HBV cure research and drug development. With the ICE-HBV in place, it should be possible to enable a HBV cure within the next decade.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Revill</LastName>
<ForeName>Peter</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Victorian Infectious Disease Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Victoria, 3010 Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Testoni</LastName>
<ForeName>Barbara</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Cancer Research Center of Lyon, INSERM U1052 and CNRS 5286, Lyon University, and Hospices Civils de Lyon, 151 Cours Albert Thomas, 69003 Lyon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Locarnini</LastName>
<ForeName>Stephen</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Victorian Infectious Disease Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Victoria, 3010 Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zoulim</LastName>
<ForeName>Fabien</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Cancer Research Center of Lyon, INSERM U1052 and CNRS 5286, Lyon University, and Hospices Civils de Lyon, 151 Cours Albert Thomas, 69003 Lyon, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2016</Year>
<Month>02</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Nat Rev Gastroenterol Hepatol</MedlineTA>
<NlmUniqueID>101500079</NlmUniqueID>
<ISSNLinking>1759-5045</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2013 Jan;57(1):399-408</RefSource>
<PMID Version="1">22806323</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gut. 2015 Jan;64(1):139-47</RefSource>
<PMID Version="1">24555998</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gut. 2012 May;61 Suppl 1:i18-24</RefSource>
<PMID Version="1">22504916</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Infect Dis. 2015 Oct;15(10 ):1167-74</RefSource>
<PMID Version="1">26189433</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gastroenterology. 2012 Sep;143(3):629-36.e1</RefSource>
<PMID Version="1">22659218</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2015 Dec;63(6):1314-22</RefSource>
<PMID Version="1">26216533</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mol Ther Nucleic Acids. 2014 Aug 19;3:e186</RefSource>
<PMID Version="1">25137139</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Virol. 2015 Dec;89(23):11945-53</RefSource>
<PMID Version="1">26378168</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AIDS Res Hum Retroviruses. 2015 Jan;31(1):36-44</RefSource>
<PMID Version="1">25257573</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Aliment Pharmacol Ther. 2008 Nov 1;28(9):1067-77</RefSource>
<PMID Version="1">18657133</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2011 Nov;55(5):996-1003</RefSource>
<PMID Version="1">21376091</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gut. 2015 Aug;64(8):1289-95</RefSource>
<PMID Version="1">25011935</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2015 Sep 1;61(5):719-29</RefSource>
<PMID Version="1">25935551</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gut. 2009 Jul;58(7):974-82</RefSource>
<PMID Version="1">19201769</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS Pathog. 2013;9(12):e1003784</RefSource>
<PMID Version="1">24367255</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Viral Hepat. 2015 Oct;22(10):842-9</RefSource>
<PMID Version="1">25765930</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS Pathog. 2013 Sep;9(9):e1003613</RefSource>
<PMID Version="1">24068929</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Antiviral Res. 2011 Nov;92(2):271-6</RefSource>
<PMID Version="1">21871497</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS Pathog. 2014 Nov 13;10(10):e1004473</RefSource>
<PMID Version="1">25393648</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Pharmacol Exp Ther. 2014 Jan;348(1):96-105</RefSource>
<PMID Version="1">24133297</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 2015 Oct 15;121(20):3631-8</RefSource>
<PMID Version="1">26177866</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2014 May;59(5):1726-37</RefSource>
<PMID Version="1">24375637</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2014 Nov 20;32(33):3736-43</RefSource>
<PMID Version="1">25287829</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gut. 2000 Mar;46(3):420-6</RefSource>
<PMID Version="1">10673308</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2014 Jul 19;384(9939):209-11</RefSource>
<PMID Version="1">25042220</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19975-9</RefSource>
<PMID Version="1">19906987</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Viral Hepat. 2015 Sep;22(9):737-53</RefSource>
<PMID Version="1">25619231</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2015 Jun;62(6):1237-45</RefSource>
<PMID Version="1">25559326</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Transpl Infect Dis. 2013 Jun;15(3):300-5</RefSource>
<PMID Version="1">23473005</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Liver Int. 2013 Feb;33 Suppl 1:116-24</RefSource>
<PMID Version="1">23286855</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2013 Sep;58(3):923-31</RefSource>
<PMID Version="1">23468172</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Virol. 2014 Sep;88(18):10412-20</RefSource>
<PMID Version="1">24872585</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Science. 2014 Mar 14;343 (6176):1221-8</RefSource>
<PMID Version="1">24557838</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Rev Immunol. 2012 Feb 24;12(3):201-13</RefSource>
<PMID Version="1">22362353</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2015 Nov;63(5):1077-85</RefSource>
<PMID Version="1">26144659</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2014 Nov 19;9(11):e113341</RefSource>
<PMID Version="1">25409334</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Int AIDS Soc. 2010;13 Suppl 3:I1, O1-16</RefSource>
<PMID Version="1">21067542</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gastroenterology. 2012 Sep;143(3):637-45</RefSource>
<PMID Version="1">22710188</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2014 Oct 7;111(40):E4244-53</RefSource>
<PMID Version="1">25201958</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Gastroenterol Hepatol. 2015 Dec;13(13):2350-2</RefSource>
<PMID Version="1">26254201</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Viral Hepat. 2011 Oct;18(10):e499-507</RefSource>
<PMID Version="1">21914069</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gut. 2015 Aug;64(8):1314-26</RefSource>
<PMID Version="1">25670809</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Commun. 2015 Mar 25;6:6588</RefSource>
<PMID Version="1">25807344</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gastroenterology. 2010 Feb;138(2):682-93, 693.e1-4</RefSource>
<PMID Version="1">19800335</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2014 Dec;61(6):1228-37</RefSource>
<PMID Version="1">25046847</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cell Mol Immunol. 2015 May;12(3):258-63</RefSource>
<PMID Version="1">25176526</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nature. 2016 Mar 17;531(7594):386-9</RefSource>
<PMID Version="1">26983541</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Antimicrob Agents Chemother. 2002 Sep;46(9):3057-60</RefSource>
<PMID Version="1">12183271</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mol Ther Nucleic Acids. 2014 Dec 16;3:e216</RefSource>
<PMID Version="1">25514649</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Infect Dis. 2012 Apr;12(4):341-53</RefSource>
<PMID Version="1">22326017</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gastroenterology. 2006 Mar;130(3):823-37</RefSource>
<PMID Version="1">16530522</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Gastroenterol Hepatol. 2013 Aug;11(8):1004-10.e1</RefSource>
<PMID Version="1">23376799</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2011 Jul 2;378(9785):73-85</RefSource>
<PMID Version="1">21511329</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2012 Mar 9;30(12):2212-9</RefSource>
<PMID Version="1">22273662</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 2012 Feb;122(2):529-37</RefSource>
<PMID Version="1">22251702</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2010 Jan;51(1):63-72</RefSource>
<PMID Version="1">19877170</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2013 Jul;58(1):98-107</RefSource>
<PMID Version="1">23213040</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Antivir Ther. 2013;18(3 Pt B):541-8</RefSource>
<PMID Version="1">23792471</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Infect Dis. 2014 Dec;29:31-6</RefSource>
<PMID Version="1">25449231</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Virol. 2005 Apr;79(7):4238-45</RefSource>
<PMID Version="1">15767425</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2014 Jul 19;384(9939):223</RefSource>
<PMID Version="1">25042224</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>JAMA. 1965 Feb 15;191:541-6</RefSource>
<PMID Version="1">14239025</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 2003 Aug;112(3):407-14</RefSource>
<PMID Version="1">12897208</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mol Ther. 2013 May;21(5):973-85</RefSource>
<PMID Version="1">23439496</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2009 Sep;51(3):581-92</RefSource>
<PMID Version="1">19616338</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gastroenterology. 2012 May;142(5):1140-1149.e3; quiz e13-4</RefSource>
<PMID Version="1">22333950</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Virol. 2002 Oct;76(20):10465-72</RefSource>
<PMID Version="1">12239323</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 1990 Sep;87(17):6599-603</RefSource>
<PMID Version="1">2395863</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Retrovirology. 2013 Nov 13;10:134</RefSource>
<PMID Version="1">24224983</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2010 Apr;52(4):616-9</RefSource>
<PMID Version="1">20185199</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gastroenterology. 2014 May;146(5):1193-207</RefSource>
<PMID Version="1">24412289</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mol Ther. 2013 Oct;21(10):1889-97</RefSource>
<PMID Version="1">23883864</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2007 Jan;45(1):102-10</RefSource>
<PMID Version="1">17187404</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6669-74</RefSource>
<PMID Version="1">15100412</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2014 Jul;60(1):87-97</RefSource>
<PMID Version="1">24585488</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Virol. 2008 Oct;82(20):10262-70</RefSource>
<PMID Version="1">18684823</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Antivir Ther. 2011;16(8):1169-86</RefSource>
<PMID Version="1">22155900</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Virol. 2013 Apr;87(8):4360-71</RefSource>
<PMID Version="1">23388725</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Antimicrob Agents Chemother. 1998 Dec;42(12):3179-86</RefSource>
<PMID Version="1">9835512</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Front Immunol. 2013 Mar 01;4:57</RefSource>
<PMID Version="1">23459859</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gastroenterology. 2016 Jan;150(1):194-205</RefSource>
<PMID Version="1">26416327</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gastroenterology. 2014 Jul;147(1):48-64</RefSource>
<PMID Version="1">24768844</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Microbiol. 2007 Dec;45(12):3942-7</RefSource>
<PMID Version="1">17942661</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Science. 2003 Feb 7;299(5608):893-6</RefSource>
<PMID Version="1">12574631</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Microbiol Infect. 2014 Nov;20(11):1173-80</RefSource>
<PMID Version="1">24975365</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Med. 2015 Jun;21(6):591-600</RefSource>
<PMID Version="1">25962123</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2013 May;58(5):861-7</RefSource>
<PMID Version="1">23246506</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2015 Oct 20;112(42):E5715-24</RefSource>
<PMID Version="1">26438841</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2011 Aug 1;204(3):415-8</RefSource>
<PMID Version="1">21742840</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Immunol. 2013 Jun;14(6):574-83</RefSource>
<PMID Version="1">23584070</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mol Cell. 1999 Jun;3(6):771-80</RefSource>
<PMID Version="1">10394365</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Expert Rev Anti Infect Ther. 2013 May;11(5):489-98</RefSource>
<PMID Version="1">23627855</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2011 Jan 27;364(4):322-31</RefSource>
<PMID Version="1">21268724</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gastroenterology. 2004 Jun;126(7):1750-8</RefSource>
<PMID Version="1">15188170</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2013 Apr;58(4):676-83</RefSource>
<PMID Version="1">23219442</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Rev Immunol. 2012 Jul 20;12 (8):607-14</RefSource>
<PMID Version="1">22814509</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2011 Oct;55(4):762-9</RefSource>
<PMID Version="1">21334391</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2008 Feb;47(2):428-34</RefSource>
<PMID Version="1">18220290</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gut. 2012 Mar;61(3):333-6</RefSource>
<PMID Version="1">22147510</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2015 Nov;63(5):1238-53</RefSource>
<PMID Version="1">26150256</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Structure. 2013 Aug 6;21(8):1406-16</RefSource>
<PMID Version="1">23871485</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nature. 2012 Jul 18;487(7407):293-4</RefSource>
<PMID Version="1">22810677</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Virol. 2010 Aug;84(16):8308-15</RefSource>
<PMID Version="1">20519397</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2009 Dec;50(6):1773-82</RefSource>
<PMID Version="1">19937696</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2013 Jan 3;368(1):34-44</RefSource>
<PMID Version="1">23281974</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055808" MajorTopicYN="N">Drug Discovery</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
<QualifierName UI="Q000458" MajorTopicYN="N">organization & administration</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014943" MajorTopicYN="Y">Global Health</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006291" MajorTopicYN="N">Health Policy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006293" MajorTopicYN="N">Health Promotion</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
<QualifierName UI="Q000458" MajorTopicYN="N">organization & administration</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019694" MajorTopicYN="N">Hepatitis B, Chronic</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007391" MajorTopicYN="Y">International Cooperation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012109" MajorTopicYN="N">Research Support as Topic</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>2</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>2</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>8</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26907881</ArticleId>
<ArticleId IdType="pii">nrgastro.2016.7</ArticleId>
<ArticleId IdType="doi">10.1038/nrgastro.2016.7</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Australie</li>
<li>France</li>
</country>
<region><li>Auvergne-Rhône-Alpes</li>
<li>Rhône-Alpes</li>
</region>
<settlement><li>Lyon</li>
</settlement>
</list>
<tree><country name="Australie"><noRegion><name sortKey="Revill, Peter" sort="Revill, Peter" uniqKey="Revill P" first="Peter" last="Revill">Peter Revill</name>
</noRegion>
<name sortKey="Locarnini, Stephen" sort="Locarnini, Stephen" uniqKey="Locarnini S" first="Stephen" last="Locarnini">Stephen Locarnini</name>
</country>
<country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Testoni, Barbara" sort="Testoni, Barbara" uniqKey="Testoni B" first="Barbara" last="Testoni">Barbara Testoni</name>
</region>
<name sortKey="Zoulim, Fabien" sort="Zoulim, Fabien" uniqKey="Zoulim F" first="Fabien" last="Zoulim">Fabien Zoulim</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D50 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001D50 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:26907881
   |texte=   Global strategies are required to cure and eliminate HBV infection.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:26907881" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Global strategies are required to cure and eliminate HBV infection.

Global strategies are required to cure and eliminate HBV infection.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki